Brivaracetam is an antiepileptic drug used as an add-on treatment, with a similar structure to that of levetiracetam.
No direct comparisons have been performed with brivaracetam and other antiepileptic drugs. A response rate near 40% has been obtained with brivaracetam 100-200 mg/day in pivotal placebo-controlled trials.
Its safety profile is similar to that of levetiracetam, although the experience is limited. Its most common adverse events include dizziness, somnolence, and fatigue.
Brivaracetam does not make any contribution to therapy as add-on treatment in patients with partial-onset seizures who are unresponsive to other antiepileptic drugs.